Огляд світового досвіду акцинопрофілактики захворювань, асоційованих із вірусом папіломи людини

Authors

  • Ф. І. Лапій NAMS, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2012.8.30-33

Abstract

Сьогодні відомо понад 100 серотипів вірусу папіломи людини (ВПЛ), що можуть уражати клітини людини. З них близько 40 серотипів здатні уражати генітальний тракт [1], а 15 серотипів є онкогенними. Серед найбільш поширених серотипів, що асоціюються з раком шийки матки (РШМ), є ВПЛ 16-го та 18-го серотипів. Ці серотипи відповідальні за 70% випадків розвитку РШМ. ВПЛ 6-го та 11-го серотипів є причиною 90% аногенітальних кондилом.РШМ посідає друге місце у світі серед видів раку, найбільш поширених у жінок. За даними ВООЗ, щорічно відмічається близько 500 тис. нових випадків захворювання та 250 тис. смертельних випадків.

Author Biography

Ф. І. Лапій, NAMS

PhD, Associate Professor of Pediatric Infectious Diseases and Immunology, Medical Science of Ukraine, National Expert of WHO vaccination, chief pediatric immunologist of Kyiv

References

  1. Munoz N. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective.Int. J. Cancer: 111, 278-285 (2004).
  2. Anhang R., Goodman A., Goldie S.J. CA Cancer J Clin. 2004; 54: 248-259.
  3. Centers for Disease Control and Prevention. Rockville, Md: CDC National Prevention Information Network; 2004.
  4. Smith J.F. et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Human vaccines, 2007, 3: 109-115.
  5. Harper D.M. et al. Sustained immunogenicity and high efficacy against HPV 16/18 related cervical neoplasia: long-term follow-up through 6.4 years in women vaccinated with Cervarix (GSK’s HPV 16/18 AS04 candidate vaccine). Presented at the Annual Meeting on Women’s Cancer of the Society for Gynecologic Oncology, Tampa, Florida, USA, 9-12 March, 2008. Abstract in Gynecologic Oncology, 2008, 109: 158.
  6. Lehtinen M., Paavonen J., Wheeler C.M. et al.Lancet Oncol. 2012; 13: 89-99.
  7. Glaxo Smith Kline clinical study register. Human Papillomavirus Types 16 and 18 Vaccine. GSK Study ID 109616 (Y7). Accessed January 26, 2012.
  8. Stanley M., Lowy D.R., Frazer I.Prophylactic HPV vaccines: underlying mechanisms. Vaccine, 2006, 24(Suppl. 3): 106-113.
  9. Olsson S.E. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine, 2007, 25: 4931-4939.
  10. Shefer A et al. Vaccine. 2008; 26S: K68-K75.
  11. Koulova A. et al. Vaccine. 2008; 26: 6529-6541.
  12. New Zealand Ministry of Health press release, 02 May 2008.
  13. Levy-Bruhl et al. Eur J Cancer. 2009; 45: 2709-2713.
  14. Cayman Island Government. Accessed 11 August, 2009.
  15. Pan American Health Organization Immunization Newsletter, Volume XXXI, Nо. 1, February 2009.
  16. Howlett R.I. et al. Preventive Medicine.2009;48: 432-437.
  17. WHO/ICO Information Center of HPV and Cervical Cancer, Fact Sheet: Croatia, 22 June, 2010. Accessed 28 September, 2010.
  18. Ireland Ministry of Health press release. http://www.dohc.ie/press/releases/2010/20100115.html. Accessed 12 February 2010.
  19. Latvia vaccination schedule. http://apps.who.int/immunization_monitoring/en/globalsummary/ScheduleResult.cfm,accessed 10 November 2010.
  20. Ministry of Health Republic of Macedonia. http://moh.gov.mk/eng/index.php?news=328&print. Accessed 11 June 2010.
  21. European Cervical Cancer Association (ECCA). HPV Vaccination Across Europe. April 2009. http://www.ecca.info/fileadmin/user_upload/HPV_Vaccination/ECCA_HPV_Vaccination_April_2009.pdf. Accessed 30 September 2010.
  22. Romania Ministry of Health press release, 11 November 2009. http://www.ms.ro/index.php?pag=62&id=6884&pg=1. Accessed 30 September 2010.
  23. Slovenia Ministry of Health press release, 27 March 2009. http://www.mz.gov.si/nc/si/splosno/cns/novica/articla/12106/5843. Accessed 29 September 2010.
  24. Cayman Island Government. http://www.gov.ky/portal/page?_pageid=1142,4547404&_dad=portal&_schema=portal. Accessed 11 August 2009.
  25. Pan American Health Organization Immunization Newsletter. Volume XXXI, Number 1 February 2009.
  26. Howlett R.I. et al. Preventive Medicine. 2009;48: 432-437.
  27. WHO/ICO Information Center of HPV and Cervical Cancer, Fact Sheet: Croatia, 22 June 2010. www.who.int/hpvcentre. Accessed 28 September 2010.
  28. WHO/ICO Information Center of HPV and Cervical Cancer, Fact Sheet: Russia, 22 June 2010. www.who.int/hpvcentre. Accessed 28 September 2010.
  29. Abu Dhabi Ministry of Health Vaccination Brochure.
  30. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56 (RR-2):1-24.
  31. Villa L.L., Costa R.L., Petta C.A. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
  32. Munoz N., Bosch F.X., de Sanjose S. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
  33. Garland S.M., Hernandez-Avila M., Wheeler C.M. et al.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356: 1928-43.

Downloads

Published

2012-12-14

How to Cite

Лапій, Ф. І. (2012). Огляд світового досвіду акцинопрофілактики захворювань, асоційованих із вірусом папіломи людини. REPRODUCTIVE ENDOCRINOLOGY, (8), 30–33. https://doi.org/10.18370/2309-4117.2012.8.30-33

Issue

No. 8 (2012)

Section

Gynecology

License

Copyright (c) 2014 Ф. І. Лапій

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.